{"id":23041,"date":"2023-01-09T23:56:00","date_gmt":"2023-01-09T15:56:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23041"},"modified":"2025-01-25T23:58:56","modified_gmt":"2025-01-25T15:58:56","slug":"pfizers-paxlovid-excluded-from-chinas-nrdl-amid-price-dispute","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23041","title":{"rendered":"Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute"},"content":{"rendered":"\n

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s (NYSE: PFE<\/a>) COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid’s exclusion. Industry observers speculated that the NHSA was seeking a price as low as RMB 700 (USD 103) per box, compared to the current price of RMB 1,890 (USD 278.96).<\/p>\n\n\n\n

Other COVID-19 Therapies in Negotiations<\/strong>
Other COVID-19 therapies involved in the negotiations included Genuine Biotech’s azvudine and the traditional Chinese medicine (TCM) \u201clung cleaning granules.\u201d Both had been filed for NRDL consideration by their respective manufacturers and had already passed the expert review stage. Azvudine and the TCM were successfully added to the NRDL, with azvudine reimbursed for its approved HIV\/AIDS indication. Genuine Biotech stated that the drug’s reimbursement price for HIV could impact its secondary use as a COVID-19 treatment.<\/p>\n\n\n\n

Temporary NRDL Coverage<\/strong>
Despite Paxlovid’s failure to enter the NRDL, temporary NRDL coverage for Paxlovid, azvudine, molnupiravir, and cold dispersing and humidifying granules remains intact until March 31, 2023, according to an earlier notice from the NHSA. This temporary coverage ensures continued access to these therapies while negotiations and further discussions are ongoing.<\/p>\n\n\n\n

Future Outlook<\/strong>
The exclusion of Paxlovid from the NRDL highlights the ongoing challenges in balancing drug pricing and accessibility. While Genuine Biotech’s azvudine and other therapies secured their place on the NRDL, the fate of Paxlovid underscores the importance of reaching mutually agreeable pricing terms. The temporary NRDL coverage provides a buffer for patients and healthcare providers, ensuring that critical treatments remain available during this transitional period.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s (NYSE: PFE) COVID-19 therapy…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[13,101,67,863,309],"class_list":["post-23041","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-policy-regulatory","tag-covid-19","tag-nationally-negotiated-drugs","tag-nhsa-prev-smia","tag-nyse-pfe","tag-pfizer"],"yoast_head":"\nPfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid's exclusion. Industry observers speculated that the NHSA was seeking a price as low as RMB 700 (USD 103) per box, compared to the current price of RMB 1,890 (USD 278.96).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23041\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23041\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T15:56:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-25T15:58:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute\",\"datePublished\":\"2023-01-09T15:56:00+00:00\",\"dateModified\":\"2025-01-25T15:58:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041\"},\"wordCount\":290,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"COVID-19\",\"Nationally negotiated drugs\",\"NHSA (prev. SMIA)\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23041#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23041\",\"name\":\"Pfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-09T15:56:00+00:00\",\"dateModified\":\"2025-01-25T15:58:56+00:00\",\"description\":\"The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid's exclusion. Industry observers speculated that the NHSA was seeking a price as low as RMB 700 (USD 103) per box, compared to the current price of RMB 1,890 (USD 278.96).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23041\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23041#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute - Insight, China's Pharmaceutical Industry","description":"The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid's exclusion. Industry observers speculated that the NHSA was seeking a price as low as RMB 700 (USD 103) per box, compared to the current price of RMB 1,890 (USD 278.96).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23041","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23041","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-09T15:56:00+00:00","article_modified_time":"2025-01-25T15:58:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23041#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23041"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute","datePublished":"2023-01-09T15:56:00+00:00","dateModified":"2025-01-25T15:58:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23041"},"wordCount":290,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["COVID-19","Nationally negotiated drugs","NHSA (prev. SMIA)","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23041#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23041","url":"https:\/\/flcube.com\/?p=23041","name":"Pfizer's Paxlovid Excluded from China's NRDL Amid Price Dispute - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-09T15:56:00+00:00","dateModified":"2025-01-25T15:58:56+00:00","description":"The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer\u2019s COVID-19 therapy Paxlovid (nirmatrelvir, ritonavir) notably absent despite widespread anticipation. The National Healthcare Security Administration (NHSA) cited a failure to agree on a price point as the reason for Paxlovid's exclusion. Industry observers speculated that the NHSA was seeking a price as low as RMB 700 (USD 103) per box, compared to the current price of RMB 1,890 (USD 278.96).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23041#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23041"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23041#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23041"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23041\/revisions"}],"predecessor-version":[{"id":23042,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23041\/revisions\/23042"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}